Literature DB >> 23645099

Effect of acute and chronic vitamin D administration on systemic renin angiotensin system in essential hypertensives and controls.

G Bernini1, D Carrara, A Bacca, V Carli, A Virdis, I Rugani, E Duranti, L Ghiadoni, M Bernini, S Taddei.   

Abstract

AIM: To investigate the systemic renin-angiotensin system (RAS) in essential hypertensives (EH) and controls (C) after short- and long-term vitamin D receptor activation.
DESIGN: Ten consecutive EH (under controlled low-salt diet) and 10 C underwent calcitriol administration (0.25 μg bid) for 1 week (Group A). Eighteen consecutive EH under angiotensin II receptor antagonist therapy received a single oral dose of 300,000 IU of cholecalciferol and were followed up for 8 weeks (Group B).
METHODS: In basal conditions and at the end of the study (1 week in Group A and 8 weeks in Group B), plasma renin activity (PRA), plasma active renin, aldosterone, and angiotensin II were evaluated, as well as blood pressure, plasma 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D [1,25(OH)2D], and PTH.
RESULTS: In Group A, plasma 25(OH)D levels in EH and C were below the normal range, although lower levels were found in the former. No association between basal plasma 25(OH)D or 1,25(OH)2D levels and blood pressure values or RAS components was observed either in the whole group or in the two subgroups. Calcitriol administration did not affect any RAS parameter either in EH or in C. In Group B, cholecalciferol significantly increased 25(OH)D and 1,25(OH)2D levels without interfering with the angiotensin II receptor antagonist-induced increase in RAS components. No correlation was found between plasma 25(OH)D or 1,25(OH)2D levels and blood pressure values or RAS parameters before and after cholecalciferol administration.
CONCLUSIONS: The present data suggest that, in our experimental conditions, vitamin D receptor activation is unable to influence systemic RAS activity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23645099     DOI: 10.1007/BF03347275

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  21 in total

Review 1.  Vitamin D deficiency.

Authors:  Michael F Holick
Journal:  N Engl J Med       Date:  2007-07-19       Impact factor: 91.245

2.  Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.

Authors:  Dick de Zeeuw; Rajiv Agarwal; Michael Amdahl; Paul Audhya; Daniel Coyne; Tushar Garimella; Hans-Henrik Parving; Yili Pritchett; Giuseppe Remuzzi; Eberhard Ritz; Dennis Andress
Journal:  Lancet       Date:  2010-11-06       Impact factor: 79.321

3.  Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline.

Authors:  Michael F Holick; Neil C Binkley; Heike A Bischoff-Ferrari; Catherine M Gordon; David A Hanley; Robert P Heaney; M Hassan Murad; Connie M Weaver
Journal:  J Clin Endocrinol Metab       Date:  2011-06-06       Impact factor: 5.958

Review 4.  Vitamin D: epidemiology of cardiovascular risks and events.

Authors:  Monica Leu; Edward Giovannucci
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2011-08       Impact factor: 4.690

5.  25-Hydroxyvitamin D is associated with plasma renin activity and the pressor response to dietary sodium intake in Caucasians.

Authors:  Anand Vaidya; John P Forman; Paul N Hopkins; Ellen W Seely; Jonathan S Williams
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2011-02-17       Impact factor: 1.636

6.  The Fok1 vitamin D receptor gene polymorphism is associated with plasma renin activity in Caucasians.

Authors:  Anand Vaidya; Bei Sun; John P Forman; Paul N Hopkins; Nancy J Brown; Nikheel S Kolatkar; Gordon H Williams; Jonathan S Williams
Journal:  Clin Endocrinol (Oxf)       Date:  2011-06       Impact factor: 3.478

7.  Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.

Authors:  Steven Fishbane; Harini Chittineni; Michal Packman; Paula Dutka; Nicole Ali; Nicole Durie
Journal:  Am J Kidney Dis       Date:  2009-07-12       Impact factor: 8.860

8.  1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system.

Authors:  Yan Chun Li; Juan Kong; Minjie Wei; Zhou-Feng Chen; Shu Q Liu; Li-Ping Cao
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

9.  Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography.

Authors:  Stefan Pilz; Winfried März; Britta Wellnitz; Ursula Seelhorst; Astrid Fahrleitner-Pammer; Hans P Dimai; Bernhard O Boehm; Harald Dobnig
Journal:  J Clin Endocrinol Metab       Date:  2008-08-05       Impact factor: 5.958

Review 10.  Vitamin D status and arterial hypertension: a systematic review.

Authors:  Stefan Pilz; Andreas Tomaschitz; Eberhard Ritz; Thomas R Pieber
Journal:  Nat Rev Cardiol       Date:  2009-08-18       Impact factor: 32.419

View more
  5 in total

1.  Investigating the association of vitamin D with blood pressure and the renin-angiotensin-aldosterone system in hypertensive subjects: a cross-sectional prospective study.

Authors:  Antoine Cremer; Chloé Tambosco; Jean-Benoît Corcuff; Romain Boulestreau; Prune Gaillard; Marion Lainé; Georgios Papaioannou; Philippe Gosse
Journal:  J Hum Hypertens       Date:  2017-12-18       Impact factor: 3.012

Review 2.  Interplay of vitamin D, erythropoiesis, and the renin-angiotensin system.

Authors:  Domenico Santoro; Daniela Caccamo; Silvia Lucisano; Michele Buemi; Katerina Sebekova; Daniel Teta; Luca De Nicola
Journal:  Biomed Res Int       Date:  2015-04-27       Impact factor: 3.411

3.  A randomized intervention study to evaluate the effect of calcitriol therapy on the renin-angiotensin system in diabetes.

Authors:  Sarah Zaheer; Kiara Taquechel; Jenifer M Brown; Gail K Adler; Jonathan S Williams; Anand Vaidya
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2018 Jan-Mar       Impact factor: 1.636

Review 4.  Is Vitamin D Supplementation an Effective Treatment for Hypertension?

Authors:  Songcang Chen; Gio Gemelga; Yerem Yeghiazarians
Journal:  Curr Hypertens Rep       Date:  2022-06-23       Impact factor: 4.592

Review 5.  The Antioxidant Therapy: New Insights in the Treatment of Hypertension.

Authors:  Daniela Sorriento; Nicola De Luca; Bruno Trimarco; Guido Iaccarino
Journal:  Front Physiol       Date:  2018-03-21       Impact factor: 4.566

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.